Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020118096 - ANTI-CANCER ACTIVITY OF ADAMANTANE DERIVATIVES

Publication Number WO/2020/118096
Publication Date 11.06.2020
International Application No. PCT/US2019/064760
International Filing Date 05.12.2019
IPC
A61K 31/13 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
13Amines, e.g. amantadine
A61K 9/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
A61K 9/16 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
14Particulate form, e.g. powders
16Agglomerates; Granulates; Microbeadlets
Applicants
  • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US]/[US]
Inventors
  • SHARABI, Andrew
Agents
  • DICKE, Alysha A.
  • FOLLETT, Angela D.
Priority Data
62/775,73105.12.2018US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) ANTI-CANCER ACTIVITY OF ADAMANTANE DERIVATIVES
(FR) ACTIVITÉ ANTICANCÉREUSE DE DÉRIVÉS DE L'ADAMANTANE
Abstract
(EN)
Provided herein are methods for treating cancer comprising administering to a subject in need thereof an adamantane derivative, or a pharmaceutically acceptable salt thereof, such as rimantadine or amantadine. In some embodiments, the adamantane derivative is PEGylated.
(FR)
L'invention concerne des méthodes de traitement du cancer comprenant l'administration à un sujet qui en a besoin d'un dérivé de l'adamantane, ou d'un sel pharmaceutiquement acceptable de celui-ci, tel que la rimantadine ou l'amantadine. Dans certains modes de réalisation, le dérivé de l'adamantane est PEGylé.
Latest bibliographic data on file with the International Bureau